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Abstract
Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder 
resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, 
protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal 
period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical 
setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including 
developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in the genes of 
either gamma-glutamyl carboxylase or vitamin K2,3-epoxide reductase complex. These two proteins are necessary for 
gamma-carboxylation, a post-synthetic modification that allows coagulation proteins to display their proper function. 
The developmental and skeletal anomalies seen in VKCFD are the result of defective gamma-carboxylation of a 
number of non-haemostatic proteins. Diagnostic differentiation from other conditions, both congenital and acquired, 
is mandatory and genotype analysis is needed to confirm the defect. Vitamin K administration is the mainstay of 
therapy in VKCFD, with plasma supplementation during surgery or severe bleeding episodes. In addition, prothrombin 
complex concentrates and combination therapy with recombinant activated FVII and vitamin K supplementation may 
constitute alternative treatment options. The overall prognosis is good and with the availability of several effective 
therapeutic options, VKCFD has only a small impact on the quality of life of affected patients.
Disease name and classification
Hereditary combined vitamin K-dependent clotting fac-
tors deficiency (VKCFD) is a rare inherited coagulation
defect that forms part of a wider group of rare disorders
named Familial Multiple Coagulation Factor Deficiencies
(FMCFDs). FMCFDs are characterized by the simultane-
ous decrease in the levels of two or more coagulation fac-
tors. The first classification of FMCFDs was proposed by
Soff and Levin in 1981 [1,2]. Recently a new classification
has been outlined (Table 1) and we currently define
FMCFDs as the presence of more than one coagulation
factor deficiency arising from a genetic defect or defects
and transmissible as a familial trait [3]. The development
of this new classification required both laboratory and
genetic recognition of patients affected by concomitant
independent defects as well as the identification of multi-
ple defects related to one single gene mutation. Three
subgroups of disorders are therefore included: i) FMCFDs
arising from single coagulation factor deficiencies ii)
FMCFDs arising from a single genetic defect iii) FMCFDs
arising from cytogenetic abnormalities [3]. Since VKCFD
arises from a single genetic defect of either γ-glutamyl
carboxylase (GGCX) or vitamin K 2,3-epoxide reductase
complex (VKORC) - two proteins of the vitamin K cycle -
in the revised classification it obviously falls in the second
subgroup.
Definition
VKCFD is a heterogeneous coagulation disorder consist-
ing of a deficiency of clotting factors II (FII), VII (FVII),
IX (FIX), X (FX), as well as the coagulation inhibitors pro-
tein C (PC), protein S (PS) and protein Z (PZ). The dis-
ease leads to a bleeding tendency with a variegate clinical
picture. Two subtypes have been identified, deriving from
mutations of two enzymes of the vitamin K cycle: VKCFD
type1 is defined by defective GGCX activity, first
reported in Devon Rex cats [4], while VKCFD type 2
derives from functional deficiency of VKORC [5].
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Epidemiolgy
VKCFD is a very rare autosomal recessive disorder, with a
low incidence (< 30 kindreds worldwide). As the disease
is inherited in an autosomal recessive manner, the male to
female ratio is 1:1. The first case of VKCFD was described
in 1966 in an infant girl who presented bleeding from the
first days of life [6]. The proband had low or undetectable
plasma levels of coagulation factors II, VII, IX and X in
the absence of any hepatic disease or malabsorption.
Only a few additional cases of VKCFD have been
reported to date [7-15]. The scientific literature in this
area is composed of single case reports and small clinical
series described in Africa, Asia, Europe and North Amer-
ica. Racial distribution, ethnic predilection and carrier
incidence are therefore unpredictable.
Clinical description
Clinical symptoms of VKCFD vary according to procoag-
ulant protein levels which depend on the availability of
vitamin K. The severity of the bleeding pattern is there-
fore influenced by both dietary intake of vitamin K and
functional status of the gut microflora, as well as by the
penetrance of the genetic defect which is widely variable.
Accordingly, in the most severe cases, onset of symptoms
occurs in newborns while a delayed recognition of the
disorder is possible in milder cases. Despite a modest
propensity to thrombosis hypothesized in milder cases
due to the deficiency of natural anticoagulants, VKCFD is
characterized by a cluster of different, often life threaten-
ing, bleeding symptoms occurring both spontaneously
and in a surgical setting. Reviewing the scientific litera-
ture on this disease, the spectrum of bleeding symptoms
appears to range from mild to severe and usually involves
skin and mucosae. Easy bruising is common. Muco-cuta-
neous bleeding, such as gastrointestinal bleeding, may
also appear spontaneously or after antibiotic therapy,
because of the decreased vitamin K production by gut
bacteria. Bleeding from the umbilical cord is reported
[6,8]. Hemarthrosis is rarely described [8]. VKCFD can
sometimes cause fatal intracranial haemorrhage in the
first weeks of life, which is similar to the haemorrhagic
disease the newborns that results form acquired vitamin
K deficiency [6,7,16]. The case of a woman with persis-
tent menorrhagia, but whose worst bleeding episodes
occurred mainly in a surgical scenario, such as post-par-
tum haemorrhage and haemoperitoneum following ovar-
ian cyst rupture, has been described [17]. Antibiotic and
anticonvulsivant therapy administration must be care-
fully evaluated as these drugs can worsen the bleeding
pattern [8].
Non-haemostatic manifestations
VKCFD-affected patients often show a variegate pattern
of non-haemostatic symptoms due to defective γ-carbox-
ylation of proteins other than the clotting factors. Devel-
opmental and skeletal abnormalities resembling those
seen in warfarin embryopathy are striking non-haemo-
static features, consisting in stippling of the long bones
epiphyses and shortness of finger distal phalanges [7,11].
Osteoporosis without the classical serum circulating
markers of bone rearrangement [11,17] and pseudoxan-
Table 1: updated classification of the FMCFDs*
FMCFDs arising from co-incidental single coagulation factor 
deficiencies:
• Combined VWD and FXI deficiency
• Combined VWD and haemophilia A
• Combined VWD and haemophilia B
• Combined haemophilia A and FXI deficiency
• Other rarer co-incidental disorders
FMCFDs arising from single genetic defects:
FMCFDs with bleeding as the dominant clinical feature:
• Combined FV and FVIII deficiency
• Combined vitamin K-dependent coagulation factor deficiency
FMCFDs with bleeding as part of a wider syndrome complex:
• Congenital disorders of glycosylation
• Noonan syndrome
• Inborn errors of liver synthetic function or bile secretion
FMCFDs arising from cytogenetic defects:
• 13q34 deletion syndromes (combined FVII and FX deficiency)
* Familial Multiple Coagulation Factor DeficienciesNapolitano et al. Orphanet Journal of Rare Diseases 2010, 5:21
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thoma elasticum-like disorders [18] have been reported.
As a consequence of the bone impairment during
embryogenesis, an increased rate of foetal loss has been
suggested by some authors. The exact incidence is still
difficult to calculate because of the rarity of the defect
[11,19].
Etiopathogenesis
As with all other coagulation factors, FII, FVII, FIX, FX
and the three anticoagulant proteins (PC, PS and PZ) are
normally synthesized in the liver. All such factors
undergo a post-translational modification of glutamate
(Glu) residues into γ-carboxyglutamate (Gla) residues.
Carboxylation, necessary for their normal activity in the
coagulation system, involves Glu  residues located in a
homologous 'Gla domain' which spans approximately 45
amino acids. Gla residues enable these proteins to adapt
to calcium-dependent conformation allowing their bind-
ing to phospholipids [20]. The γ-carboxylation is held in
the endoplasmic reticulum and is catalyzed by the
enzyme GGCX which is hypothesized to bind to the pro-
peptide coagulation factors at their amino terminus. Car-
boxylated proteins are then transported to the Golgi for
secretion and the propeptide sequence is then removed
[21,22]. Vitamin K is an essential cofactor for GGCX and
when a carbon dioxide is added to Glu to form Gla, the
reduced form of vitamin K (vitamin K hydroquinone) is
oxygenated to form vitamin K 2,3 epoxide. At this stage
the enzyme VKORC is needed to regenerate the vitamin
K hydroquinone, completing the so called vitamin K cycle
[21] (Figure 1). Three forms of vitamin K are known:
i)vitamin K1 (Phylloquinone) which is abundant in green
and leafy vegetables and is produced by plants and algae;
ii)vitamin K2 (Menaquinones) which is a mixture of mol-
ecules produced by the microbial intestinal flora and dif-
fers from K1 by unsaturated side chains of isoprenoid
units with different length; iii)vitamin K3 (Menadione)
which is a synthetic form and is more water-soluble.
In VKCFD abnormal carboxylase function arises from
defects in the genes encoding either the GGCX (VKCFD
type 1) or the VKORC (VKCFD type 2). In both cases the
disorder leads to under-carboxylation and comparable
reduction in the activities of several proteins including
vitamin K-dependent clotting factors. GGCX was iso-
lated in 1991 by forward genetics and to date several
point mutations have been detected [23,24]. One excep-
tion is a 14 bp deletion in intron 1, which is supposed to
be involved in the protein expression [13]. VKCFD type 1
has been shown to result from compound heterozygosity
of missense mutations in the GGCX  gene [19,25-27].
VKOR was identified 34 years ago [28] but its biochemis-
try has been difficult to understand because of refractori-
ness to purification. Both isolation and characterization
of VKOR were performed only in 2004 by reverse genet-
ics and expression cloning [29]. The wider knowledge of
this protein has amplified the interest of the scientific
community in this rare disease. Only one mutation has
been recognized to be causative of VKCFD in three dif-
ferent kindreds of Lebanese, German and Italian origin: a
single 292C > T nucleotide substitution in the VKOR
complex subunit 1 (VKORC1) that causes the amino acid
change Arg98Trp [30,31] in a position close to the vita-
min K binding site. Remarkably, mutations other than the
Arg98Trp influence the response to vitamin K intake dur-
ing oral anticoagulation, encoding for resistance to warfa-
rin treatment [32]. VKCDF is therefore a natural model
that resembles oral anticoagulation with vitamin K antag-
onists and treatment of this disease can be used to test
different modalities to reverse warfarin overdose, whose
most feared and dramatic complication is intracranial
haemorrhage.
GGCX and VKORC are also involved in the post-trans-
lational processing of non-haemostatic proteins. These
include: osteocalcin, PROX and matrix-Gla protein
(MGP) expressed in the connective tissue [33]; Gas 6, a
protein related to protein S but involved in the process of
phagocytosis of apoptotic cells [34,35]; nephrocalcin A-D
[36]; several putative carboxylated proteins identified
through nucleotide database screening such as proline
rich Gla protein 1 (PRGP1) and 2 (PRGP2), transmem-
brane Gla protein 3 (TMG3) and 4 (TMG4) [37]. Most
non-haemostatic manifestations that complete the clini-
cal picture in individuals affected by VKCFD are
explained by defective synthesis of these proteins. A list
of haemostatic and non-haemostatic proteins requiring
γ-carboxylation to display proper function is reported in
table 2.
The last remarkable pathogenetic aspect of this rare
coagulation defect is the role that under-carboxylated
factors (PIVKA) may play as signal messengers. In partic-
ular, it has been demonstrated that Des-γ-carboxypro-
thrombin (PIVKA-II), besides being a prognostic marker
of hepatocellular carcinoma (HCC), can bind to a recep-
tor for hepatocyte growth factor named Met, and has a
role as an autologous growth factor for HCC via activat-
ing the well known Jak/STAT signalling pathway [38-40].
As vitamin K is the mainstay of treatment of VKCFD, a
disease with circulating PIVKA, understanding the kinet-
ics of γ-carboxylation will help to explore the role of this
compound as an adjuvant in HCC treatment, which is
currently under investigation.
Diagnosis and differential diagnosis
Diagnosis of VKCFD requires anamnestic differentiation
from acquired forms of the disorder attributable to intes-
tinal malabsorption of vitamin K in the case of inflamma-
tory bowel diseases or celiac disease, severe liver
dysfunction during liver cirrhosis or accidental ingestionNapolitano et al. Orphanet Journal of Rare Diseases 2010, 5:21
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of warfarins and superwarfarins. Such conditions must be
excluded with certainty before raising the suspect of the
disease. A vitamin K assay with a normal result would be
useful for screening them but it is usually only performed
in selected research laboratories only. In addition,
VKCFD must be distinguished by other congenital clot-
ting defects. These include: single coagulation defects
such as haemophilia B (FIX deficiency); isolated deficien-
c i e s  o f  F V I I ,  w h i c h  i s  c o n s i d e r e d  t h e  m o s t  f r e q u e n t
among rare coagulation disorders; the rarest FII and FX
deficiencies, as well as combined defects like combined
FVII and FX deficiency. The latter is the result of chro-
mosomal abnormalities (chr13q deletions) as the genes
encoding for the two factors are located very close in the
chromosome 13. Among acquired bleeding disorders, a
distinction from the presence of circulating antibodies
with inhibitory function such as acquired haemophilia or
the very rare presence of inhibitors against FVII is man-
datory. VKCFD usually becomes evident because of an
excessive bleeding pattern compared to the decreased
levels of each of the clotting factors involved, but clinical
distinction is not always easy and requires precise labora-
tory assessment as well as genotype confirmation.
Laboratory assessment is characterized by prolonged
prothrombin time (PT) and activated partial thrombo-
plastin time (aPTT). The extent to which the PT and
aPTT are prolonged may be influenced by the degree to
which each individual coagulation factor is decreased.
FII, FVII, FIX and FX activity levels can show variably
reduced values. The first clotting factor usually assayed is
FVII, because it has the shortest half life, with the PT
slightly more prolonged than the aPTT. Abnormal PT
and aPTT shorten after mixing with normal plasma. PC,
PS and PZ activities are also reduced but, as mentioned,
an increased thrombotic risk in VKCFD has only been
anecdotally reported [13]. Once seriously suspected,
genotyping of VKORC (spanning 5 kb and containing 3
exons on chromosome 16) [29] and GGCX (spanning 13
kb and containing 15 exons on chromosome 2) [41] can
be performed in selected research laboratories. This test
is mandatory in order to exactly define a complex coagu-
lation defect that must be distinguished from many
acquired conditions as well as from other single or multi-
ple congenital coagulation defects.
Antenatal diagnosis
There is no report in the scientific literature for antenatal
diagnosis in VKCFD. Considering that the disease can be
easily treated with vitamin K, the advantages deriving
from the procedure are nonessential compared to the
Figure 1 the vitamin K cycle.Napolitano et al. Orphanet Journal of Rare Diseases 2010, 5:21
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potential bleeding complications. Administration of vita-
min K in the third trimester of pregnancy in women sus-
pected to carry a child with VKCFD would avoid major
haemorrhages in the newborn.
Treatment
Vitamin K administration is the mainstay of therapy in
VKCFD. Nevertheless response to treatment is extremely
variable depending both on the administration route and
on individual sensitivity to vitamin K [20]. Mildly affected
patients can be treated with oral vitamin K which usually
only partially corrects the clotting times as restoration of
carboxylated coagulation factors is incomplete. However
such treatment prevents major haemorrhages. Adminis-
tration of an oral dose of 10 mg twice or three times per
week usually avoids frequent muco-cutaneous bleeding.
Alternatively, if not tolerated perorally, the same dose of
vitamin K can be regularly administered intravenously at
intervals which can vary according to the prothrombin
time - international normalized ratio (PT-INR) values. It
is important to remark that, despite the generally
acknowledged efficacy of vitamin K, a fixed therapeutic
schedule does not exist for this rare disease. Additional
information on the kinetics of vitamin K-dependent clot-
ting factors come from two recent studies in which the
modifications of coagulation phenotype after an intra-
venous 10 mg single dose of vitamin K have been tested
in VKCFD type2. Such a dose proved to be clinically ben-
eficial and able to provide valuable patterns of factor spe-
cific biosynthesis, half-life and decay [17,31]. Unlike other
authors have reported [42], restoration of the four coagu-
lation factors was virtually complete with amelioration of
the clotting times starting at the 4-hour post-infusion
assay. Normalization of the PT-INR was obtained at the
24 -hour post-infusion assay. The effect was still present
compared to the patient's basal PT-INR at the 72-hour
post-infusion assay. Of the two natural anticoagulants,
PC behaved similarly to the other vitamin K-dependent
coagulation proteins, while PS levels where only partially
restored. Reasons for such differences need further inves-
tigation but as a whole, these studies indicate that the fast
improvement of the clotting times is due to the rapid
release of the coagulation factors accumulated in the
uncarboxylated form and undergoing γ-carboxylation,
while the sustained normalization results from γ-carbox-
ylation of proteins of 'de novo' synthesis. Differences in
the synthetic pattern may exist for each factor. Further-
more, other reductating pathways, which work with less
intensity under physiologic conditions, may contribute to
reconstitute the reduced form of vitamin K when satu-
rated by external administration [43,44].
Treatment challenges remain regarding the manage-
ment of both major surgery and the most severe bleeding
episodes. Such occurrences need to be managed in a spe-
cific environment such as haemophilia centres. Insights
in this field would improve knowledge about warfarin
reversal to which this rare disease resembles both clini-
cally and biologically. This is one of the most debated
issues among blood coagulation specialists and most
information about how to treat VKCFD derive from war-
farin reversal.
Plasma supplementation during surgery or overt haem-
orrhage is indicated. The recommended dose is 15-20
mL/Kg of body weight given intravenously, to be repeated
until clinical efficacy and amelioration of clotting times.
The requirement of multiple administrations to reach
Table 2: haemostatic and non-haemostatic proteins 
requiring γ -carboxylation to display proper function
Coagulation Factor MW (KDa)
Factor II 72
Factor VII 50
Factor IX 55
Factor X 58.9
Protein C 62
Protein S 69
Protein Z 68
Bone Proteins
Osteocalcin 58
Matrix Gla protein 10
Others
Gas 6 Protein 75
Nephrocalcin 14
PRGP1 23
PRGP2 17
TIMG3 25.8
TIMG4 25.4Napolitano et al. Orphanet Journal of Rare Diseases 2010, 5:21
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efficient clotting may be complicated by circulatory over-
load [45].
Prothrombin Complex Concentrates (PCCs) are a
series of products containing factors II, VII, IX and X as
well as PC and PS at variable concentrations. All PCCs
contain factors II, IX and X: those with negligible amount
of FVII are commonly known as 3-factor PCCs while, if
the amount of FVII is substantial, the product is labelled
4-factor PCC. Both 3 and 4-factor PCCs could also be
successfully administered in VKCFD considering their
efficacy in reversing warfarin anticoagulation [46]. Spe-
cific experience in VKCFD is unreported and therapeutic
schedules are therefore derived from the treatment of
warfarin reversal, with a suggested dose of 500 U given
intravenously (median 8.8 U/Kg) for a PT-INR below 5
[46]. The risk of transmission of blood-born pathogens,
although theoretically possible, is extremely low due to
viral inactivating procedures, while a low but significant
thrombotic risk must be taken into account [47].
Recombinant activated FVII (Eptacog alfa (activated))
(rFVIIa, Novoseven® Novo Nordisk, Copenhagen, Den-
mark) is a powerful drug with a short half-life (< 4 h)
belonging to the so called "by-passing agents". It is indi-
cated for the treatment of haemophilia complicated by
the presence of anti-factor VIII (FVIII) inhibiting anti-
bodies which impair the use of FVIII concentrates. Addi-
tional indications are congenital FVII deficiency and
Glanzmann's disease but rFVIIa has been successfully
used in a number of off-label bleeding situations includ-
ing warfarin overdose or critical bleeding during warfarin
treatment within the normal range [48]. It was success-
fully used in VKCFD during an emergency minor surgical
setting [17]. A total dose of 1.2 mg (~ 20 μgr/Kg of body
weight) provided a sudden normalization of the PT-INR
with the shortest value at the 4-hour post-infusion assay
as expected because of the increased FVII. Interestingly, a
double rate increase in FII, FIX and FX activities was
detected, remarking the role of rFVIIa as a powerful acti-
vator of the whole coagulation system, a finding that only
a complex defect with multiple factors deficiency allowed
the opportunity to explore. Since rFVIIa and vitamin K
show different peaks of action (4 hours and 24 hours
respectively), their combined use with a simultaneous
infusion at the above mentioned doses can obtain a sus-
tained normalization of clotting times to be used in case
of major bleeding and more complex surgical procedures.
This "combination therapy" is a feasible alternative option
for life-threatening bleeding episodes in VKCFD.
Prognosis
All the mentioned therapeutic options make VKCFD a
disease with good prognosis and a low impact on the
quality of life, with permanent disabling consequences
only resulting in severely affected patients who have been
diagnosed after critical events such as intracranial haem-
orrhage.
Unresolved questions and future research 
directions
VKCFD is a very rare disease, but its peculiar pathoge-
netic mechanism emphasizes its importance far beyond
an audience of coagulation specialists. Warfarin is a drug
taken by millions of patients worldwide but still has some
bleeding complications feared by most practitioners. Sen-
sitivity and resistance to warfarin depend basically on
single nucletide polymorphisms of both VKORC  and
Cytochrome p450 2C9 genes. Understanding the biologi-
cal steps from synthesis to secretion of coagulation fac-
tors make VKCFD a tool to add additional information in
warfarin dose finding and dose limiting studies. Advances
in the treatment of VKCFD would help to minimize
bleeding complications occurring during oral anticoagu-
lation with vitamin K antagonists by administering a
combination of drugs with different mechanisms and
peaks of action.
Defective carboxylation of non-haemostatic proteins is
still an open issue in some widespread diseases: post-
menopausal women show higher circulating levels of
uncarboxylated osteocalcin compared to pre-menopausal
women [49]. Furthermore, in patients with inflammatory
bowel diseases, the malabsorption of fats including lipo-
soluble vitamins results in skeletal impairment. Increas-
ing knowledge in this field discloses a possible role for
vitamin K supply.
As a last important research field, the regulation of the
vitamin K cycle and the signalling driven by under-car-
boxylated clotting factors in HCC opens new horizons for
vitamin K as an adjuvant in cancer therapy.
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